HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A double-blind study of domperidone in the symptomatic treatment of chronic post-prandial upper gastrointestinal distress.

Abstract
Oral domperidone (30 mg/day) or placebo tablets were given to 41 patients presenting with symptoms of chronic post-prandial dyspepsia, in a double blind study. The tablets were taken three times a day before meals. The first part of the study lasted four weeks and was followed by a second four week period in which domperidone was given on an open basis to all subjects. At the end of the double-blind phase all indices but one (bitter regurgitation) as well as the gastro-oesophageal reflux cluster had significantly improved on domperidone treatment while none had done so on placebo. During the subsequent open four weeks of domperidone all items improved in both study groups. No side effects were seen in any of the participants in the study.
AuthorsK Haarmann, F Lebkuchner, A Widmann, W Kief, M Esslinger
JournalPostgraduate medical journal (Postgrad Med J) Vol. 55 Suppl 1 Pg. 24-7 ( 1979) ISSN: 0032-5473 [Print] England
PMID382149 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antiemetics
  • Benzimidazoles
  • Piperidines
  • Placebos
Topics
  • Adult
  • Aged
  • Antiemetics (therapeutic use)
  • Benzimidazoles (therapeutic use)
  • Chronic Disease
  • Clinical Trials as Topic
  • Double-Blind Method
  • Dyspepsia (drug therapy)
  • Female
  • Food
  • Humans
  • Male
  • Middle Aged
  • Piperidines (therapeutic use)
  • Placebos

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: